ViiV Healthcare Begins Phase III Programme with dolutegravir

rilpivirine Combination for HIV Maintenance Therapy

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

Stichworte

Channel

ViiV Healthcare

Keine Aussenderdaten vorhanden.

Rückfragen & Kontakt

Contacts: ViiV UK/US Media enquiries: Sebastien Desprez,
+44(0)7920-567-707; Marc Meachem, +1-919-483-8756; GSK Global Media
enquiries: Kathleen Cuca, +1-215-859-1922; David Daley,
+44(0)20-8047-5502;
Melinda Stubbee, +1-919-483-2510; Analyst/Investor enquiries: Ziba
Shamsi,
+44(0)20-8047-5543; Tom Curry, +1-215-751-5419; Gary Davies,
+44(0)20-8047-5503; James Dodwell, +44(0)20-8047-2406; Jeff
McLaughlin,
+1-215-751-7002